Marc Goodman
Stock Analyst at Leerink Partners
(2.92)
# 1,661
Out of 4,989 analysts
92
Total ratings
56.16%
Success rate
28.11%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $14.32 | +249.16% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $13.31 | -24.87% | 5 | May 7, 2025 | |
| OPT Opthea | Downgrades: Market Perform | $12 → $1 | $3.41 | -70.67% | 2 | Mar 25, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $116.00 | +29.31% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $1.53 | -34.64% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $42.27 | -24.30% | 1 | Apr 15, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $70.20 | -64.39% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $12.75 | +292.16% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $6.29 | +217.97% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $145.23 | -20.82% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $142.50 | +117.54% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $16.20 | -25.93% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $36.95 | +24.49% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $24.42 | -14.00% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $128.30 | +63.68% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.45 | +308.16% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $27.79 | -2.84% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $4.93 | +204.26% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $521.47 | -48.22% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $222.47 | -56.85% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $45.02 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $81.51 | -17.80% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $21.26 | +360.96% | 7 | Oct 5, 2017 |
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $14.32
Upside: +249.16%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $13.31
Upside: -24.87%
Opthea
Mar 25, 2025
Downgrades: Market Perform
Price Target: $12 → $1
Current: $3.41
Upside: -70.67%
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $116.00
Upside: +29.31%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $1.53
Upside: -34.64%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $42.27
Upside: -24.30%
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $70.20
Upside: -64.39%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $12.75
Upside: +292.16%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.29
Upside: +217.97%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $145.23
Upside: -20.82%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $142.50
Upside: +117.54%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $16.20
Upside: -25.93%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $36.95
Upside: +24.49%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $24.42
Upside: -14.00%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $128.30
Upside: +63.68%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.45
Upside: +308.16%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $27.79
Upside: -2.84%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $4.93
Upside: +204.26%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $521.47
Upside: -48.22%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $222.47
Upside: -56.85%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $45.02
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $81.51
Upside: -17.80%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $21.26
Upside: +360.96%